当前位置：
X-MOL 学术
›
Ther. Adva. Endocrinol. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
Therapeutic Advances in Endocrinology and Metabolism ( IF 3.8 ) Pub Date : 2022-11-22 , DOI: 10.1177/20420188221139101 Felix Grabherr 1 , Christoph Grander 1 , Maria Effenberger 1 , Julian Schwärzler 1 , Herbert Tilg 2
Therapeutic Advances in Endocrinology and Metabolism ( IF 3.8 ) Pub Date : 2022-11-22 , DOI: 10.1177/20420188221139101 Felix Grabherr 1 , Christoph Grander 1 , Maria Effenberger 1 , Julian Schwärzler 1 , Herbert Tilg 2
Affiliation
Metabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a...
中文翻译：
MAFLD：脂肪肝疾病重新定义的 2 年教会了我们什么
代谢功能障碍相关脂肪肝病 (MAFLD) 已成为全球主要的肝病。而术语非酒精性脂肪性肝病 (NAFLD) 主要反映了...
更新日期：2022-11-23
中文翻译：
MAFLD：脂肪肝疾病重新定义的 2 年教会了我们什么
代谢功能障碍相关脂肪肝病 (MAFLD) 已成为全球主要的肝病。而术语非酒精性脂肪性肝病 (NAFLD) 主要反映了...
京公网安备 11010802027423号